Emerging Therapies

Chicago, IL—Immunotherapy with the anti–PD-1 agent nivolumab (Opdivo) prolonged survival in patients with nonsquamous non–small-cell lung cancer (NSCLC) as second-line therapy for disease progression with standard platinum-based therapy, based on results of CheckMate 057, which were presented at the 2015 American Society of Clinical Oncology meeting.
Chicago, IL—The results of the phase 3 GADOLIN trial provide the first proof of efficacy for obinutuzumab (Gazyva) in patients with indolent non-Hodgkin lymphoma (NHL). Obinutuzumab added to standard bendamustine (Treanda) chemotherapy almost doubled progression-free survival (PFS) in patients with rituximab (Rituximab)-refractory indolent lymphoma—the median PFS was 29.2 months with obinutuzumab plus bendamustine versus 14 months with bendamustine alone.
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease. The study appeared online July 20, 2015, in Nature Medicine.
San Francisco, CA—With new signaling pathways being explored, established drug classes expanding across the tumor spectrum, and immunotherapies investigated across tumor types, the hematology pipeline is abundant. Here are some of the most promising compounds in development presented at ASH 2014.
San Francisco, CA—Many of the presentations at the 2014 annual meeting of the American Society of Hematology centered on the abundance of new molecules being developed for hematologic cancers, including new immunotherapies, and drugs that are expanding from one tumor type to another.
The cancer drug pipeline continues to boast many new therapies, reinforcing the recent trends of new and improved monoclonal antibodies and other classes of targeted therapies for different types of tumors.

New Orleans, LA—Novel options for the treatment of patients with hematologic conditions are in the pharmaceutical pipeline, with many drugs showing promising results. Here is a look at key studies presented at the 2013 American Society of Hematology annual meeting.

Chronic Lymphocytic Leukemia
Phase 3 studies of idelalisib demonstrated impressive progression-free survival (PFS) in previously treated patients with chronic lymphocytic leukemia (CLL).

New York, NY—Targeted therapy to the B-cell receptor signaling is paying off in chronic lymphocytic leukemia (CLL) and in other B-cell lymphomas. Two novel oral agents—the PI3K inhibitor idelalisib and the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib—show great promise for these malignancies. These drugs have been studied in phase 3 trials, and current studies are focusing on combination strategies and new schedules to improve outcomes. In addition, both drugs have recently been submitted for review by the US Food and Drug Administration (FDA).

San Antonio, TX—The addition of an oral investigational agent to letrozole (Femara) for the treatment of estrogen receptor (ER)-positive metastatic breast cancer more than tripled the time spent in remission compared with endocrine therapy alone, according to a study reported at the CTRC-AACR San Antonio Breast Cancer Symposium.

Page 3 of 3
Results 21 - 30 of 30
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology